Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Labopharm completes US$113.7 million cross-border public offering

Fasken
Reading Time 1 minute read Subscribe
Client

Labopharm Inc.

On May 3, 2006, Labopharm inc., an international specialty pharmaceutical company focused on improving existing drugs incorporating Contramid, the company's proprietary advanced controlled-release technology, completed a public offering of 12,650,000 common shares at a price of $8.99 per share for total estimated gross proceeds to the company of $113.7 million. The offering, which was made in Canada and in the United States under the Multijurisdictional Disclosure System, was Labopharm's initial public offering in the US. The company's common shares are now listed on the TSX and on NASDAQ. Labopharm was represented in-house by Lynda Covello, general counsel and corporate secretary, and in Canada by Fasken Martineau with a team that included Louis-François Hogue, Frédéric Boucher, Marie-Josée Vincelli, Alexis Steinman, Lucie Dufour (IP) and Gilles Carli (tax) as well as Julie Gauvreau (IP) of affiliate firm Goudreau Gage Dubuc.

    Subscribe

    Receive email updates from our team

    Subscribe